RecruitingNCT06767462
An Ophthalmic Safety Study in Patients With Breast Cancer
A Multicentre Study Assessing Ophthalmic Safety in Patients With Breast Cancer
Sponsor
AstraZeneca
Enrollment
160 participants
Start Date
Mar 4, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
To assess ophthalmic health in parallel cohorts of patients with breast cancer
Eligibility
Min Age: 18 YearsMax Age: 130 Years
Plain Language Summary
Simplified for easier understanding
This is an eye safety monitoring study for patients who are already enrolled in a separate breast cancer treatment trial. It involves regular eye exams to detect any potential vision side effects from the experimental breast cancer treatment being tested in the main study.
**You may be eligible if...**
- You are already enrolled and receiving treatment in a qualifying breast cancer clinical trial
- You completed a baseline eye exam before starting the breast cancer treatment
- You signed consent for both the main study and this eye safety sub-study
**You may NOT be eligible if...**
- You were not assigned to receive the experimental treatment in the main study
- You are allergic to eye-dilating drops or cannot safely undergo standard eye exam procedures
- The investigator determines participation is not appropriate for you
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(75)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06767462